It's hard to compare. The ibrutinib patient pop failed chop-Rituxan (with or without Rituxan maintenance) and potentially velcade (50 of the 115 pts). OR was 68%, CR - 21%, PFS - 13.9 mo
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.